Kadimastem Ltd

KMSTFOTCHealthcare

$3.21

$-0.10(-3.02%)

Market Cap$9503988

P/E Ratio—

52W High$9.07082

52W Low$0.6404

Avg Volume40K

Open$3.30

Beta0.57

Free Cash Flow Financials Revenue

Kadimastem Ltd (KMSTF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

KMSTF · free cash flow · updated Jun 9, 2026

Core FCF metrics

KMSTF · FCF · TTM · margin & CAGR

Free cash flow was −$2.8M for FY2024 (fiscal year ending 2024-12-31), up 75.0% year-over-year

FY2024 Free Cash Flow−$2.8M▲ +75.0% YoY

Trailing 12M (TTM)−$2.2Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

KMSTF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2024Latest−$2.8M(0M)−$2.8M▲ +75.0%—

FY2023−$11.1M(0M)−$11.1M▲ +46.2%—

FY2022−$20.0M(1M)−$20.6M▲ +6.5%—

FY2021−$21.5M(1M)−$22.1M▼ 0.4%—

FY2020−$21.8M(0M)−$22.0M▼ 0.6%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

KMSTF · P/FCF · FCF yield · FCF per share

Kadimastem Ltd (KMSTF) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2024 · 2024-12-31

Cash flow statement summary

KMSTF · cash flow statement · operating / investing / financing

For FY2024, Kadimastem Ltd generated −$2.8M in operating cash flow and spent 0M in capital expenditures, yielding −$2.8M in free cash flow.

Operating Activities

−$2.8M

Cash from core business operations

2024-12-31

Investing Activities

+$0.6M

CapEx, acquisitions & investments

2024-12-31

Financing Activities

+$0.4M

Buybacks, dividends & debt

2024-12-31

FCF FormulaOperating CF (−$2.8M) − |CapEx| (0M) = FCF (−$2.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

KMSTF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Kadimastem LtdYOU

KMSTF

−$2.8M+75.0%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Kadimastem Ltd (KMSTF) reported free cash flow of −$2.8M for FY2024 (fiscal year ending 2024-12-31), up 75.0% year-over-year.

Kadimastem Ltd has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 13 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

KMSTF free cash flow · 8 questions

Kadimastem Ltd free cash flow was −$2.8M for FY2024, up 75.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$2.2M.

KMSTF free cash flowKMSTF FCFKMSTF FCF 2024KMSTF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Kadimastem Ltd · Kadimastem Ltd SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026